Trinomab
Developer of antibody biopharmaceuticals and provider of related research services.
Launch date
Employees
Market cap
-
Enterprise valuation
$413—619m (Dealroom.co estimates Nov 2022.)
Zhuhai Guangdong (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | CNY300m | Seed | |
CNY450m | Series A | ||
* | CNY750m | Late VC | |
Total Funding | $206m |